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[5 7] ABSTRACT 
A composition is provided for the treatment of conta 
gious equine metritis, a contagious venereal disease of 
horses. The composition appears to function as a biolog 
ical inhibitor and has antibacterial and antifungal activ 
ity when applied to the normal ?ora and secretions of 
the epidermis and mucous membranes. Also, the com 
position has antipruritic and anti-in?ammatory activity. 
The composition is efficacious in the treatment of le 
sions produced by bacteria, fungi, allergies, viruses, 
trauma, and burns to the epidermis, dermis, muscles and 
mucous membranes of the surface or in body cavities of 
animals and man. 
The composition preferably comprises an aqueous solu 
tion of dextrose, citric acid and a buffering mixture of 
the salts of citric acid and acetic acid to provide an 
optional pH between 3.0 to 6.5 for various wound le 
510115. 
21 Claims, No Drawings 
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COMPOSITION FOR TOPICAL AND INFUSION 
TREATMENT OF WOUNDS AND BURNS 
2 
mal and muscular burns and wounds, which composi 
tion comprises an aqueous solution of dextrose or dex 
trose metabolite, a buffering mixture of weak organic 
acids and alkali metal salts of weak organic acids, and a 
CROSS REFERENCE TO RELATED 5 carrier, the composition being characterized as a vis 
APPLICATIONS cous solution having a pH varying from 3.0 to 6.5 de— 
This application is a continuation in part of Ser. No. Pending 0?‘ lesion type‘ Also PmYided by Fhe preserft 
409,180, ?led Aug 18’ 1932’ now Us. pat NO_ invention is a method for application of this composi 
4’483’851. tion to epidermal burns and wounds, particularly those 
10 infected with Pseudomonas, which comprises topically 
FIELD OF THE INVENTION applying the composition to the affected area. 
This invention relates to novel compositions and their DETAILED DESCRIPTION OF THE 
use in epidermal burns, and more particulary to novel INVENTION 
compositions useful for the treatment of epidermal mus 
cous membranes and muscular burns and wounds or 15 AS POhlted Out above, the Present invention is 60n 
lesions in animals and humans by topical and infusion Cefned With novel compositions and a method for the 
application of the composition. treatment of epidermal burns and wounds, particularly 
those infected with Pseudomonas. The composition 
BACKGRQUND inhibits growth of the pseudomonas on the injured area, 
There is disclosed in my parent application, Ser. No. 20 and promotes healing in burns and wounds. The compo 
409,180, ?led Aug. 18, 1982, now US. Pat. No. sition of the present invention in its broadest embodi 
4,483,85l, the disclosure of which is hereby incorpo- ment comprises an aqueous solution of dextrose or dex 
rated by reference, a composition for topically relating trose metabolite, a buffering mixture of weak organic 
equine metritis comprising the following formulation in acids and/or alkali metal salts of weak organic acids, 
water in a concentration of about 40 to 60 weight per- 25 and a carrier, the solution being characterized as a rela 
cent: tively viscous solution having a pH ranging from about 
3.0 to 6.5. 
_ _ The most preferred composition may be character 
lngred‘em Pans by We‘ght ized as containing the following formulation per liter of 
Dextrose ZW-NW 30 solution: 
Buffering Mixture 49-110 
Carrier Bil-11¢ 
Ingredient Parts by Weight 
These compositions are applied topically to the exter- Dextrose sit-50¢ 
nal genitalia of both male and female horses affected 35 Buffering MiXture 54% 
with contagious equine metritis. In several trials the came’ SW15“ 
composition was found to be 100% effective in curing 
the diseases if used on two successive days. By compari- This composition also contains about 600 to 1200 
son, antibiotics used in the prior art had to be used at parts of water, and optionally about 5 to 100 parts of an 
least ?ve days to be effective, and then were not 100% 40 alkali metal salt of acetic acid. Preferably, the composi 
effective. tion contains citric acid and an alkali metal salt of citric 
It has now been discovered that this and related com- acid as important buffering components. 
positions are broadly effective in treatment of Pseudo- The dextrose component of the composition is dex 
monas aeruginosa infected burn patients and infected trose or a dextrose metabolite which is effective to 
skin and muscle wounds. When the composition of the 45 provide antibacterial and antifungal properties to the 
invention is applied to skin burns or wounds, it provides composition when used in admixture with the other 
dramatic relief of pain, and dramatically accelerates the components. Thus the dextrose or equivalent material is 
healing process. an important component in the composition. 
_ The buffering mixture is also an important ingredient 
SUMMARY OF THE INVENTION 50 of the composition. A suf?cient amount of buffer should 
It is accordingly one object of the present invention be present to provide a resulting solution having a pH of 
to provide a novel antibacterial composition. about 3.0 to 6.5, most preferably in the range of 3.2 for 
A further object of the invention is to provide novel antipruritic properties and 6.5 for wounds and burns. 
compositions and methods for the treatment of bacterial Any buffer or mixture of buffers can be used for this 
and fungal infections. 55 purpose although mixtures of weak organic acids and 
A still further object of the present invention is to alkali metal salts of organic acids are especially pre 
provide a topical composition and methods for its use in ferred. The amount of buffering agent present is also 
the treatment of topical conditions such as burns, blis- important since the total solution should contain about 
ters and infections. 7 to 15 weight percent of buffering agent for a suitable 
An even further object of this invention is to provide 60 composition. 
a method for treating Pseudomonas infected epidermal The preferred buffering agents are polycarboxylic 
and muscular burns and wounds. ' acids, phosphates, and the like which will provide the 
Other objects and advantages of the present invention required pH range. The most preferred buffers, how 
will become apparent to those skilled in the art as the ever, comprise a mixture of hydroxy polycarboxylic 
description thereof proceeds. 65 acids having about 3 to 8 carbon atoms and their alkali 
In satisfaction of the foregoing objects and advan 
tages there is provided by this invention an antibacterial 
and antifungal composition for the treatment of epider 
metal salts, or mixtures thereof. Preferred organic acids 
include citric acid, malic acid, tartronic acid, tartaric 
acid, and mixtures thereof as well as the sodium and 
4,600,711 
3 
potassium salts of these acids. A highly preferred buff 
ering system comprises a mixture of citric acid and 
sodium citrate. 
The composition optionally contains an alkali metal 
salt of acetic acid in an amount of about 1 to 4 parts by 
weight. The preferred alkali metal salt is sodium ace 
tate, although any alkali metal salt of acetic acid may be 
used. The salt functions to increase the antifungal activ 
ity of the compound. This has also been shown to im 
part a longer shelf life to the composition. When the 
composition contains the alkali metal salt of acetic acid, 
the antifungal activity is improved so that it will not 
support the growth of bacteria or fungi. 
It is also preferred that the resulting solution be a 
viscous solution to inhibit drainage from the infected 
organs after topical application. Thus, a carrier vehicle 
is included in the composition to increase the viscosity 
of the solution. Suitable carriers include polyalkylene 
glycols, methyl cellulose and the like. The preferred 
carrier vehicle is a lower polyalkylene glycol such as 
glycerine. 
The carrier also provides the proper consistency to 
the composition so that the composition has suf?cient 
viscosity for topical application. It also provides the 
necessary consistency to the solution so it can be used as 
a lubricant in the treatment of animals such as horses. 
A preferred formulation of the invention comprises 
the following components per liter of solution: 
Ingredient Parts by Weight 
Dextrose 591-500 
Hydroxy carboxylic acid 2.5 to IM 
Alkali metal salt of 2.5 to M0 
hydroxy carboxylic acid 
Carrier SQ-lS? 
In a more preferred aspect of the invention, the com 
position would also contain an alkali metal salt of acetic 
acid in an amount of about 5 to 100 parts per liter of 
solution. Additionally, the remainder of the solution is 
preferably water. 
The most preferred composition for use in the present 
invention comprises the following components: 
Ingredient Amount 
Dextrose 5¢0 grams 
Citric acid 1015 grams 
Sodium citrate 50 grams 
Glycerine 1% cc 
Sodium acetate 2.5 grams 
Distilled water 9% cc 
The addition of sodium acetate in the most preferred 
embodiment increases the anti—fungal activity of the 
compound. The sodium acetate containing compound 
was shown to have longer shelf life than the same com 
pound without sodium acetate, since it will not support 
the growth of bacteria or fungi. 
The resulting composition is an aqueous solution with 
suf?cient consistency to drain slowly. In use for treat 
ment of contagious equine metritis, the composition is 
applied topically directly to the external genitalia of 
stallions and mares and preferably is used one time each 
day for at least two successive days. An effective 
amount is simply a thorough application of the viscous 
solution to the external genitalia manually. It has been 
found that this method will provide 100% effectiveness 
5 
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4 
in curing horses of the contagious equine metritis organ 
ism-caused disease. 
Although the composition was originally developed 
for treatment of contagious equine metritis, it has been 
found that the composition is also effective against 
Pseudomonas infections where the infection occurred 
on the external genitalia of the affected horses. This 
discovery led to the discovery of use of the composition 
of the invention for burn patients and patients with skin 
and muscle wounds infected with Pseudomonas bac 
terias, particularly Pseudomonas aeruginosa. When the 
composition was applied to accidental skin burns, it not 
only gave dramatic relief of pain, but also prevented the 
blistering of the epidermis as well as dramatically accel 
erating wound healing. The same results were obtained 
in several cases with skin burns from sun, steam, heat, 
friction and grease. 
The compound was also shown to accelerate the 
healing of contact (allergenic) dermatitis. When the 
compound was applied at the time of exposure to poison 
ivy, the skin lesions of poison ivy did not develop. 
When applied to early cases, the compound was shown 
to be antipruritic within a few minutes of application, 
and greatly accelerated the healing of the skin lesions. 
Similar relief and reduction of swelling was observed in 
cases of insect-induced skin reactions. The composition 
is also useful in healing burns caused by friction, chemi 
cal and heat. 
In experiments involving skin and wound lesions of 
dogs, cats, cattle and horses, the composition of the 
invention was shown to greatly accelerate the healing 
of super?cial and deep skin and muscle wounds. It not 
only prevented bacterial and fungal infections of the 
wound, but it dramatically hastened the healing of the 
wound and the new growth of skin thereover. In nu 
merous cases of animal wounds involving cats, dogs, 
cattle and horses, the composition dramatically pro 
moted complete wound healing after other “state of the 
art” medical treatments failed to produce satisfactory 
results. 
Although the exact mechanism by which the compo 
sition works is not known, it was originally developed 
to enhance the normal bacteria flora of the skin to pro 
duce an anti-bacterial-like metabolite to inhibit the 
growth of the contagious equine metritis (CEM) organ 
ism. In addition to the production of the antibacterial 
metabolite, it appears that the rapid healing of wounds 
caused by the composition of the invention provides an 
environment that discourages the growth of pathogenic 
bacteria and fungi. 
Further, the composition has other bene?cial proper 
ties and functions, including anti-pruritic properties, 
reduction of tissue ?uids in epidermal vesicles and 
wound lesions, increased circulation to wound lesions 
and inhibition of bacterial and fungal growth in 
wounds. 
In preliminary tests on numerous cases of burns and 
naturally induced viral, bacterial, fungal, allergic and 
traumatic diseases of the eye, external ear, nose, oral 
mucosa, periodontal tissues, external genitalia, vagina, 
uterus, perianal and dermal tissue, and muscles affected 
with deep wound lesions, the composition was shown 
to dramatically accelerate the healing of lesions in the 
mucous membranes, epidermis, dermis and muscles. 
With the exception of neoplasia, the compound was 
effective on any type of lesion. 
The following examples are to illustrate the inven 
tion, but the invention is not to be considered as limited 
4,600,711 
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thereto. In the examples and throughout the speci?ca 
tion, parts are by weight unless otherwise indicated. 
EXAMPLE 1 
The following composition was prepared: 
Ingredient Parts by Weight 
Dextrose 250 grams 
Citric acid 50 grams 
Sodium citrate 25 grams 
Glycerine 1% cos. 
Water 4WD ccs. 
The resulting composition was a viscous solution 
having a pH of 3.20. 
To show the effectiveness of the compound on CEM, 
twenty horses were selected for testing. Each of the 
twenty horses was treated with a single treatment of the 
solution by manually applying topically directly to the 
external genitalia of the horses. From this test, 17 of the 
horses were found to be cured by the single treatment. 
The three horses which were not cured with the single 
treatment were then treated again with two successive 
treatments which were found to successfully cure the 
disease. Accordingly, in the ?eld it is recommended 
that the disease be treated one time per day with appli 
cation of the composition on at least two successive 
days. 
EXAMPLE 2 
The following composition is prepared: 
Ingredient Parts by Weight 
Distilled water 9% cc. 
Glycerine 1% cc. 
Dextrose 59¢ grams 
Citric acid 1% grams 
Sodium citrate 5Q! grams 
Sodium acetate 2.5 grams 
The resulting composition is a viscous solution hav 
ing a pH of 3.0. The compound of the invention is topi 
cally applied to ten patients having second degree epi 
dermal heat burns. In all ten cases, the patients experi 
ence dramatic relief of pain, and no blistering of the 
burn area occurs. Further, the healing time of the burn 
is dramatically accelerated. In addition, none of the 
patients develop Pseudomonas aeruginosa infections in 
the area of the burn. Similar results are obtained in cases 
where the skin burns are caused from sun, steam, fric 
tion and grease. 
The invention has been described herein with refer 
ence to certain preferred embodiments. However, as 
obvious variations thereon will become apparent to 
those skilled in the art, the invention is not to be consid» 
ered as limited thereto. 
I claim: 
1. A composition for the treatment of bacterial infec 
tions which comprises dextrose in an aqueous based 
mixture including a buffer present in suf?cient amounts 
to provide a pH in the range of from 3.0 to 6.5, and a 
carrier; said composition comprising the following: 50 
to 500 parts by weight of dextrose, 5 to 200 parts by 
weight of buffer comprising a mixture of hydroxy car 
boxylic acids and alkali metal salts of hydroxy carbox 
ylic acids, 50 to 150 parts by weight of a carrier to 
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increase viscosity of the composition, and about 5 to 100 
parts by weight of an alkali metal salt of acetic acid. 
2. A composition for the treatment of fungal infec 
tions which comprises dextrose in an aqueous based 
mixture including a buffer present in suf?cient amounts 
to provide a pH in the range of from 3.0 to 6.5, and a 
carrier; said composition comprising the following: 50 
to 500 parts by weight of dextrose, 5 to 200 parts by 
weight of buffer comprising a mixture of hydroxy car 
boxylic acids and alkali metal salts of hydroxy carbox 
ylic acids, 50 to 150 parts by weight of a carrier to 
increase viscosity of the composition, and about 5 to 100 
parts be weight of an alkali metal salt of acetic acid. 
3. A composition according to claim 2 which com 
prises about 50 to 500 parts of dextrose, about 25 to 100 
parts of a hydroxy carboxylic acid, about 2.5 to 100 
parts of an alkali metal salt of a hydroxy carboxylic 
acid, and about 50 to 150 parts of a polyalkylene glycol 
carrier. 
4. A composition according to claim 1 wherein the 
bacterial infection is a Psuedomonas infection. 
5. A composition according to claim 1 or 2 wherein 
the components of the composition are contained in a 
40-60 weight percent concentration in water. 
6. A composition according to claim 1 which com 
prises about 50 to 500 parts of dextrose, about 25 to 100 
parts of a hydroxy carboxylic acid, about 2.5 to 100 
parts of an alkali metal salt of a hydroxy carboxylic 
acid, and about 50~l50 parts of a carrier. 
7. A composition according to claim 6 or 3 wherein 
the hydroxy polycarboxylic acid component is selected 
from the group consisting of citric acid, tartronic acid, 
malic acid, tartaric acid, and mixtures thereof. 
8. A composition according to claim 6 or 3 wherein 
the alkali metal salt of the hydroxy polycarboxylic acid 
is selected from the group consisting of sodium and 
potassium salts of citric acid, tartronic acid, malic acid, 
tartaric acid, and mixtures thereof. 
9. A composition according to claim 6 or 3 wherein 
the carrier is a polyalkylene glycol. 
10. A composition according to claim 1 or 2 which 
comprises 250 parts dextrose, 50 parts citric acid, 25 
parts sodium citrate, 100 ccs. glycerine and 400 ccs. 
water, said composition being in the form of a viscous 
solution having a pH in the range of 3.2. 
11. A composition according to claim 1 or 2 compris 
ing: 
Ingredient Parts by Weight 
Dextrose 5% grams 
Citric acid libtb grams 
Sodium citrate 593 grams 
Glycerine 1% cc 
Sodium acetate 2.5 grams 
Distilled water 90¢ cc 
12. A method for the treatment of epidermal and 
muscular burns which comprises topical application of 
an effective amount to the burn area of an aqueous 
based mixture of dextrose, a buffer present in sufficient 
amounts to provide a pH in the range of about 3.0 to 4.5 
and a carrier. 
13. A method for the treatment of epidermal and 
muscular wounds which comprises topical application 
of an effective amount to the wound area of an aqueous 
based mixture of dextrose, a buffer present in sufficient 
4,600,711 
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amounts to provide a pH in the range of about 3.0 to 4.5 
and a carrier. 
14. A method according to claim 12 or 13 where the 
components of the composition are contained in a 40-60 
weight percent concentration in water and are present 
in the following amounts by weight: 
Ingredient Parts by Weight 
Dextrose 56-500 grams 
Buffer 5-2Q? grams 
Carrier 50-5¢¢ grams 
15. A method according to claim 12 or 13 wherein the 
composition comprises about 50-500 parts of dextrose, 
about 25-100 parts of hydroxy carboxylic acid, about 
25-100 parts of an alkali metal salt of a hydroxy carbox 
ylic acid, and about 50-150 parts of a carrier. 
16. A method according to claim 12 or 13 wherein the 
hydroxy polycarboxylic acid component is selected 
5 
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from the group consisting of citric acid, tartronic acid, 
malic acid, tartaric acid, and mixtures thereof. 
17. A method according to claim 12 or 13 wherein the 
alkali metal salt of the hydroxy polycarboxylic acid is 
selected from the group consisting of sodium and potas 
sium salts of citric acid, tartronic acid, malic acid, tar 
taric acid, and mixtures thereof. 
18. A method according to claim 12 or 13 wherein the 
carrier is a polyalkylene glycol. 
19, A method according to claim 12 or 13 wherein the 
composition additionally comprises an alkali metal salt 
of acetic acid. 
20. A method according to claim 12 or 13 wherein the 
burn or wound site is infected with Pseudomonas. 
21. A method for the treatment of contact dermatitis 
which comprises applying the composition of claim 1 or 
2 topically to the site of the contact dermatitis. 
5% * * * * 
